Improvement in matrix metalloproteinase-3 independently predicts low disease activity at 52 weeks in bio-switch rheumatoid arthritis patients treated with abatacept

To explore predictive factors including MMP-3 for achievement of low disease activity (LDA) at 52 weeks in bio-switch rheumatoid arthritis (RA) patients treated with abatacept, for whom obtaining a good clinical response can be difficult. Participants were 423 consecutive patients with RA treated wi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical and experimental rheumatology 2020-09, Vol.38 (5), p.933-939
Hauptverfasser:	Takemoto, Toki, Takahashi, Nobunori, Kida, Daihei, Kaneko, Atsushi, Hirano, Yuji, Fujibayashi, Takayoshi, Kanayama, Yasuhide, Hanabayashi, Masahiro, Yabe, Yuichiro, Takagi, Hideki, Oguchi, Takeshi, Kato, Takefumi, Funahashi, Koji, Matsumoto, Takuya, Sobue, Yasumori, Nishiume, Tsuyoshi, Suzuki, Mochihito, Yokota, Yutaka, Terabe, Kenya, Asai, Shuji, Ishiguro, Naoki, Kojima, Toshihisa
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!